Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Tislelizumab plus zanubrutinib bij Richter-transformatie: een fase II-studie
mrt 2024 | Leukemie, Lymfoom